Canada markets close in 1 hour 33 minutes

Sutro Biopharma, Inc. (S09.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
6.50-0.15 (-2.26%)
As of 09:15AM CET. Market open.

Sutro Biopharma, Inc.

111 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 881 6500
https://www.sutrobio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees259

Key Executives

NameTitlePayExercisedYear Born
Mr. William J. Newell J.D.CEO & Director1.06MN/A1958
Mr. Edward C. AlbiniCFO & Sec.596.4kN/A1958
Dr. Trevor J. HallamPres of Research & Chief Scientific Officer882.83k467.17k1959
Ms. Jane Chung R.Ph.Chief Commercial Officer832.52kN/A1971
Dr. James R. Swartz Ph.D., Sc.D.FounderN/AN/AN/A
Dr. Shabbir T. AnikChief Technical Operations OfficerN/AN/A1953
Ms. Annie J. Chang M.B.A.VP of Investor RelationsN/AN/AN/A
Mr. David Pauling J.D., M.A.Gen. CounselN/AN/AN/A
Ms. Linda A. FitzpatrickChief People & Communications OfficerN/AN/A1957
Dr. Nicki Vasquez Ph.D.Chief Portfolio Strategy & Alliance OfficerN/AN/A1963
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Corporate Governance

Sutro Biopharma, Inc.’s ISS Governance QualityScore as of February 1, 2023 is 6. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.